Research Papers

25 of 3333 papers

CSV Excel
Quick filters: Open Data Open Code Pre-registered Funding Declared COI Declared Open Access Clear Filters
Estrogenicity of Styrene Oligomers: Response to Ohno et al.
Ohyama KI; Nagai F.
Environ Health Perspect (Unknown)
Published: 2002
The health and management of poultry production.
Hofacre CL.
Int J Infect Dis (Unknown)
Published: 2002
New directions for drug discovery in psychiatric disease.
Speeding M; Sebban C; Perret L.
Unknown Journal
Published: 2002
Neonatal disconnection of the rat hippocampus: a neurodevelopmental model of schizophrenia.
Lipska BK.
Unknown Journal
Published: 2002
Simulating the anhedonia symptom of depression in animals.
Moreau JL.
Dialogues Clin Neurosci (Unknown)
Published: 2002
Anatomic magnetic resonance imaging studies of attention-deficit/hyperactivity disorder.
Castellanos FX.
Dialogues Clin Neurosci (Unknown)
Published: 2002
Challenges in the development of clinical trials for major depressive disorder: lessons learned from trials in minor de…
Rapaport MH; Maddux RE.
Dialogues Clin Neurosci (Unknown)
Published: 2002
Estrogen and neuroprotection: from clinical observations to molecular mechanisms.
Dubal DB; Wise PM.
Dialogues Clin Neurosci (Unknown)
Published: 2002
1/6 Transparent
Funding Declared
Research on serotonin and suicidal behavior: neuroendocrine and molecular approaches.
Corrêa H; Romano-Silva MA; Duval F; Campi-Azevedo AC; Lima V; Macher JP.
Dialogues Clin Neurosci (Unknown)
Published: 2002
1/6 Transparent
Funding Declared
Sleep-wake mechanisms and drug discovery: sleep EEG as a tool for the development of CNS-acting drugs.
Staner L.
Dialogues Clin Neurosci (Unknown)
Published: 2002
Functional neuroimaging as a direct probe of the effects of gonadal steroid hormones on the brain.
Berman KF.
Dialogues Clin Neurosci (Unknown)
Published: 2002
Subtyping of psychiatric disorders: implications for drug development.
Cancro R; E Roy J; Chabot R; Prichep L.
Dialogues Clin Neurosci (Unknown)
Published: 2002
Human models as tools in the development of psychotropic drugs.
Gilles C; Schunck T; Erb G; Namer IJ; Hodé Y; Nedelec JF; Boeijinga P; Luthringer R; Mâcher JP.
Dialogues Clin Neurosci (Unknown)
Published: 2002
Enhancing synaptic plasticity and cellular resilience to develop novel, improved treatments for mood disorders.
Quiroz JA; Manji HK.
Dialogues Clin Neurosci (Unknown)
Published: 2002
Pathophysiological aspects of diversity in neuronal inhibition: a new benzodiazepine pharmacology.
Möhler H.
Unknown Journal
Published: 2002
Placebo response in depression.
Sonawalla SB; Rosenbaum JF.
Unknown Journal
Published: 2002
Neurogenetics of emotional reactivity to stress in animals.
Chaouloff F.
Unknown Journal
Published: 2002
Nonpharmacological treatments for anxiety disorders.
Cottraux J.
Unknown Journal
Published: 2002
The clinical pharmacology of depressive states.
Schulz P; Macher JP.
Dialogues Clin Neurosci (Unknown)
Published: 2002
Japanese pharmaceutical and regulatory environment.
Nagata R; Rafizadeh-Kabe JD.
Unknown Journal
Published: 2002
Melatonin.
Pévet P.
Unknown Journal
Published: 2002
Childhood predictors of states of anxiety.
Kagan J.
Dialogues Clin Neurosci (Unknown)
Published: 2002
1/6 Transparent
Funding Declared
Developments in antipsychotic therapy with regard to hypotheses for schizophrenia.
Ackenheil M; Weber K.
Dialogues Clin Neurosci (Unknown)
Published: 2002
Transcranial magnetic stimulation: a new tool in the fight against depression.
Grunhaus L; Dannon PN; Gershon AA.
Dialogues Clin Neurosci (Unknown)
Published: 2002
Psychopharmacology of anxiety disorders.
Cassano GB; Baldini Rossi N; Pini S.
Dialogues Clin Neurosci (Unknown)
Published: 2002